Fin Trust Capital Advisors, LLC Vericel Corp Transaction History

Fin Trust Capital Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.65 - $27.37 $4,041 - $6,267	-229 Reduced 85.77%	38 $1,000
Q3 2022 Oct 20, 2022	SELL	$22.62 - $32.54 $1,221 - $1,757	-54 Reduced 16.82%	267 $7,000
Q2 2022 Jul 26, 2022	SELL	$22.88 - $39.45 $480 - $828	-21 Reduced 6.14%	321 $9,000
Q1 2022 May 03, 2022	BUY	$31.69 - $43.29 $538 - $735	17 Added 5.23%	342 $13,000
Q4 2021 Feb 14, 2022	BUY	$35.2 - $52.6 $2,745 - $4,102	78 Added 31.58%	325 $13,000
Q2 2021 Aug 16, 2021	BUY	$47.2 - $67.81 $7,080 - $10,171	150 Added 154.64%	247 $13,000
Q1 2021 May 17, 2021	BUY	$30.93 - $59.48 $3,000 - $5,769	97 New	97 $5,000

284

49.2M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.75B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.